{{Rsnum
|rsid=4149081
|Gene=SLCO1B1
|Chromosome=12
|position=21225087
|Orientation=plus
|GMAF=0.2525
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLCO1B1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 31.0 | 68.1
| HCB | 22.6 | 45.3 | 32.1
| JPT | 16.8 | 44.2 | 38.9
| YRI | 1.4 | 27.9 | 70.7
| ASW | 5.3 | 31.6 | 63.2
| CHB | 22.6 | 45.3 | 32.1
| CHD | 28.4 | 40.4 | 31.2
| GIH | 0.0 | 12.9 | 87.1
| LWK | 3.6 | 28.2 | 68.2
| MEX | 1.7 | 17.2 | 81.0
| MKK | 4.5 | 28.2 | 67.3
| TSI | 3.9 | 37.3 | 58.8
| HapMapRevision=28
}}
{{PMID Auto
|PMID=19901119
|Title=Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects
|OA=1
}}

{{PharmGKB
|RSID=rs4149081
|Name_s=OATP1B1: intronic A/G
|Gene_s=SLCO1B1
|Feature=Intron
|Evidence=PubMed ID:19901119
|Annotation=Risk or phenotype-associated allele: G allele, with additive genotypic effect. Phenotype: Genome-wide analysis of 398,699 germline SNPs showed association of the rs4149081 G allele with increased methotrexate (MTX) plasma clearance, with an additive effect per G allele (increase of 12.7 mL/min/m(2) per allele in 434 subjects), after adjusting for age, race, sex, and MTX regimen. Variants rs11045879 and rs4149081 were in linkage disequilibrium (r(2) = 1). The G allele was associated with increased risk of gastrointestinal toxicity (mucositis) (OR = 15.3, p = 0.03). Pharmacokinetics differed by ethnicity (MTX clearance: African>Caucasian). Study size: 434 (discovery cohort), 206 (independent validation cohort), 640 (combined cohort). Study population/ethnicity: Multiethnic children (5.92 median age , 1.02-18.85 range) with ALL given 3,014 courses of methotrexate at 2-5 g/m(2) enrolled in Tennessee. Significance metric(s): increased MTX clearance: p = 1.7 x 10(-9) (n = 434), p = 0.017 (n = 206), p = 6.7 x 10(-10) (n = 640); increased GI toxicity: OR = 15.3, p = 0.03. Type of association: CO; GN; PK; ADR; TOX
|Drugs=methotrexate
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA165110327
}}

{{PMID Auto
|PMID=21387541
|Title=Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia
}}

{{PMID Auto GWAS
|PMID=21886157
|Trait=None
|Title=Human metabolic individuality in biomedical and pharmaceutical research.
|RiskAllele=A
|Pval=3E-22
|OR=0.2090
|ORtxt=None
|OA=1
}}

{{PMID Auto
|PMID=22668755
|Title=Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4149081
|overall_frequency_n=19
|overall_frequency_d=120
|overall_frequency=0.158333
|n_genomes=17
|n_genomes_annotated=0
|n_haplomes=18
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}